Mucosal vaccine formulations for targeted therapy of HPV cancers
We obtained preliminary evidence for an alternate safer approach of HPV peptide vaccination using two adjuvants with superior capacity to enhance vaccine-mediated immunity and recognized for their safety in human clinical trials. This proposal will build on these encouraging data towards preclinical confirmation of the safety and efficacy of this vaccination along with understanding the underlying mechanisms for future implementation in human clinical testing against HPV+ cervical and oral cancers.
Academic Research; vaccine research
Cervix Uteri, Head and Neck, Vagina
The University of Texas M.D. Anderson Cancer Center